Jefferies analyst Michael Leuchten assumed coverage of AstraZeneca (AZN) with a Buy rating and 15,000 GBp price target Given what the firm sees as likely outperformance of in-market oncology franchises and the biopharma pipeline, the firm argues that the company’s 2030 $80B sales target is “in sight and is lower risk than perceived.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s New Obesity Drug Study: What Investors Need to Know
- AstraZeneca’s AZD4604: Promising Developments in Asthma Treatment
- Trump Trade: Trump administration prepares new probe into pharma prices
- AstraZeneca, Amgen’s Tezspire approved in EU as add-on therapy
- Trump admin prepares new probe into U.S. pharma prices, FT says